ML Bio Solutions, Inc.
ML Bio Solutions, Inc.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) | autosomal recessive limb-girdle muscular dystrophy type 2I | Active, not recruiting | Phase 3 | 2026-09-09 | NCT05775848 | |
| Study of BBP-418 in Patients With LGMD2I | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, autosomal recessive limb-girdle muscular dystrophy type 2I, hereditary disease, limb-girdle muscular dystrophy, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Active, not recruiting | Phase 2 | 2026-07-21 | NCT04800874 | |
| Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9 | autosomal recessive limb-girdle muscular dystrophy type 2I | Active, not recruiting | Phase 3 | 2026-07-02 | NCT07678775 |